Ocular Therapeutix Inc. shares surged as much as 13.5% in pre-market trade Monday after the company said its eye treatment had positive topline results in a late-stage clinical trial. The company said Dextenza, an insert intended to treat eye inflammation and pain after surgery, met primary efficacy endpoints for both. Dextenza failed to get Food and Drug Administration approval in late July, but Ocular said it planned to resubmit its application with the agency by the end of the year and would file for a post-surgical eye pain indication if approved. Ocular shares dropped 26.7% year-to-date, compared with a 5.9% rise in the S&P 500 .
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below